New CEO for Merz Therapeutics: Stefan König
1.3.2023 18:06:00 EET | Business Wire | Press release
As of immediately, Stefan König will be responsible for Merz Therapeutics GmbH as CEO and Managing Director. As one of the businesses of Merz Group, Merz Therapeutics provides medical solutions for the treatment of serious health conditions such as neurological health impairments or diseases of the liver.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230301005731/en/
Stefan Koenig, CEO Merz Therapeutics (Photo: Business Wire)
Stefan König is an accomplished leader who has successfully worked in the pharmaceutical industry for his entire career, both at national and international market level. “Merz Therapeutics has had a successful development in last years. That is why we are very pleased to have won an exceptional executive with Stefan König who will continue to expand our business and take it to the next level. His profound expert knowledge in both clinical-stage drug development and commercialization as well as his experience in different global markets make him the ideal person to drive the future growth strategy of Merz Therapeutics,” says Phillip Burchard, CEO of the Merz Group and Chairman of the Merz Holding Board.
Until recently, Stefan König held the position of President and CEO of George Medicines, a London-based company focusing on the development of pharmaceuticals in an advanced clinical phase. George Medicines is a spin-off of the George Institute, one of the leading international health research institutes. Before this, Stefan König worked for many years at Takeda Pharmaceuticals, where he held various senior positions in global, regional and local functions. Among others, he was responsible for the global Inflammatory Bowel Disease franchise, after heading up a number of local and regional market organizations.
After a strategic reorganization three years ago, Merz Group created Merz Therapeutics as one of its three core businesses, with the goal for each of the individual businesses to have a better focus on specific customers and markets. Since then, Merz Therapeutics has developed favourably. The previous CEO and Managing Director of Merz Therapeutics, Stefan Brinkmann, is leaving Merz by best mutual agreement at the end of February after many years. With Stefan König’s appointment as of March 1, 2023, we will ensure a seamless transition.
About the Merz Group
The Merz Group is a global, diversified health care company based in Frankfurt, Germany. Family-owned for over 110 years, the company is distinguished by its commitment to innovation, a long-term perspective, and a focus on sustainable, profitable growth. The Merz Group includes the businesses Merz Aesthetics, Merz Therapeutics, Merz Consumer Care, Merz Real Estate, and Merz Financial Investments. The company employs 3,730 people (as of financial year 21/22) in 28 countries worldwide. To learn more, please visit www.merz.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230301005731/en/
Contact information
Merz Pharma GmbH & Co. KGaA
Communications
Karolina Dzeko-Balke
Telephone number: +49 (0) 69 1503 2749
E-mail: karolina.dzeko-balke@merz.de
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Verdict Expected Soon in Klarna’s $8.3 Billion Antitrust Lawsuit Against Google24.2.2026 20:09:00 EET | Press release
Klarna Group plc (NYSE: KLAR) announces that the Patent and Market Court of Sweden (Patent- och marknadsdomstolen) is expected to deliver its verdict on April 15, 2026 in the antitrust damages proceedings brought by Klarna’s subsidiary PriceRunner International AB against Google LLC and Google Ireland Limited. The trial, which ran from October 20 to December 19, 2025, concerned PriceRunner’s claim for approximately $8.3 billion in damages — the largest civil damages claim ever filed in a Swedish court. The Case The claim arises from Google’s abuse of dominance in online comparison shopping, as established by the European Commission in a binding 2017 decision and upheld without reservation by the Court of Justice of the European Union in September 2024. PriceRunner alleges that Google systematically demoted competing price comparison services in its search results while favouring its own Google Shopping product, causing sustained and quantifiable commercial damage to PriceRunner over mo
INRIX Announces New Generation of AI Traffic Products: Helping to Improve Safety, Reduce Congestion, and Enhance Mobility Operations24.2.2026 17:49:00 EET | Press release
INRIX, a global leader in transportation data and analytics, today announced a major expansion of its Trafficfamily of products, delivering innovativeAI-driven capabilities to help transportation agencies and logistics organizations move from reactive traffic management to proactive, safety-focused and efficient operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260224267928/en/ INRIX introduces expanded automation, generative AI capabilities, enhanced incident detection, and continuous analytics. Over twenty years ago, INRIX commercialized the first system to use GPS data to create real-time traffic information. In 2019, INRIX launched AI Traffic – the world's first traffic platform to leverage deep learning models and AI to improve the quality and analysis globally. Now, INRIX is launching a new generation of automation and intelligence to help agencies and enterprises move faster from analyzing data to making deci
Check Point and ControlPlane Partner to Help Enterprises Securely Scale AI and Accelerate Agentic Innovation24.2.2026 16:30:00 EET | Press release
ControlPlane, a specialist AI Security and DevSecOps consultancy, and Check Point Software Technologies Ltd., a pioneer and global leader in cyber security solutions, today announced a strategic collaboration to help enterprises securely adopt Large Language Models (LLMs) and agentic AI systems at scale. The partnership delivers a comprehensive, regulator-ready security framework designed to reduce risk, protect sensitive data, and enable organizations to move confidently from AI experimentation to production deployment. By combining Check Point’s AI-native threat prevention platform with ControlPlane’s deep expertise in cloud native architectures and DevSecOps, enterprises can operationalize AI securely without slowing innovation. As organizations advance AI initiatives beyond pilots, they face a growing “AI readiness gap.” Emerging threats such as prompt injection, unauthorized access, data leakage, and model misuse introduce risks that traditional security controls were not built to
Andersen Consulting Expands Capabilities with Assure Consulting24.2.2026 16:30:00 EET | Press release
Andersen Consulting strengthens its platform with addition of collaborating firm Assure Consulting, a Germany-based management consulting firm specializing in project management and project portfolio management. Founded in 2003, Assure Consulting supports organizations in successfully delivering complex projects and transformations. The firm helps clients establish and operate Project Management Offices (PMOs), strengthen governance and portfolio management, and apply classical, agile, or hybrid project management approaches tailored to their needs. Assure Consulting also provides hands-on support for large-scale system and process rollouts, integrated change management for organizational and cultural transformation, and coaching and training programs aligned with internationally recognized project management standards to build sustainable capabilities within client organizations. “This collaboration allows us to scale our project-delivery expertise and agile transformation capabilitie
Clinilabs Establishes EU Headquarters in Basel, Strengthening European Clinical Operations Under New Regional Leadership24.2.2026 16:00:00 EET | Press release
Clinilabs, a leading specialty contract research organization (CRO) focused on central nervous system (CNS) drug and device development, today announced the expansion of its European operations, including the establishment of its European Union headquarters at Switzerland Innovation Park Basel Area, and the appointment of Dr. Anne-Marie Nagy as executive vice president and head of Clinilabs Europe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260224669284/en/ Dr. Anne-Marie Nagy appointed as Executive Vice President and Head of Clinilabs Europe Switzerland Innovation Park Basel Area is part of Switzerland’s national innovation network and located within the Basel region’s globally recognized life sciences cluster, bringing together biopharma companies, research institutions, and clinical innovation leaders. “Europe is a critical pillar of Clinilabs’ long-term growth strategy,” said Gary K. Zammit, Ph.D., president and chie
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom